Loading…
Pulmonx Corp
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -95.1% over 5Y.
today you would have $53.09▼ -94.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 6 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $2.21 | $6.79 | $12.75 | $8.43 | $32.07 | $69.02 | |
| P/S | 6.5x | 1.0x | 3.2x | 7.2x | 5.9x | 24.5x | 75.3x |
| P/B | 3.7x | 1.7x | 3.1x | 4.2x | 2.1x | 6.1x | 10.9x |
| EPS | -$1.33 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ALDXAldeyra Therapeutics, Inc. | $1.40 | — | 2.2x | — | -49.48% | $84.16M |
| ACETAdicet Bio, Inc. | $9.15 | — | 0.8x | — | -78.08% | $85.61M |
| INCRIntercure Ltd. | $5.78 | — | 0.8x | — | -9.27% | $86.72M |
| ECORelectroCore, Inc. | $9.63 |
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Company description provided by Yahoo Finance.
| -$1.44 |
| -$1.60 |
| -$1.59 |
| -$1.35 |
| -$3.16 |
| Profit margin | -93.53% | -59.67% | -67.30% | -88.60% | -109.80% | -100.51% | -98.47% |
| ROE | -44.84% | -99.79% | -65.72% | -51.42% | -38.26% | -25.18% | -14.25% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| — |
| — |
| $86.78M |
| CTORCitius Oncology Inc | $0.78 | — | 2.0x | — | -126.58% | $82.03M |
| ZYBTZhengye Biotechnology Holding Ltd | $1.73 | — | 2.2x | — | -25.17% | $81.99M |